The detection of human pancreatic cancer-associated antigen in the serum of cancer patients

✍ Scribed by Yong S. Chung; Jenny J. L. Ho; Young S. Kim; Hajime Tanaka; Bunzo Nakata; Akihito Hiura; Hiroyuki Motoyoshi; Katsusuke Satake; Kaoru Umeyama

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 766 KB
• Volume: 60
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19871001)60:7<1636::aid-cncr2820600736>3.0.co;2-c

✦ Synopsis

A radioimmunoassay (RIA) test for human pancreatic cancer-associated antigen (Span-I) was developed to evaluate the diagnosis of various gastrointestinal disorders. Serum Span-1 in normal subjects ranged from 5 to 275 lJ/ml, with a mean of 58.8 U/ml (k58.7, standard deviation). All control subjects had levels of less than 400 U/ml. Study subjects, 93% with pancreatic cancer, 59% with hepatubiliary cancers, 23% with gastric cancers, and 13% with colonic cancers had serum Span-1 levels greater than 400 U/ml. Sensitivities of Span-I, CA 19-9. and Dupan-2 for pancreatic cancer were 94%. 85%, and 38% respectively. Span-1 in patients with Stage I pancreatic cancer showed a 50% positive rating but CA 19-9 and Dupan-2 showed only 0% and 25%. Although a positive rating of these three antibodies increased in advanced cases, Span-I showed the highest positive rating. Span-1 reacted with colonic cancer tissues with Lewis' b-phenotype. However, none of these tissues did not react against CA 19-9. From these results, Span-I has a good predictive value for detecting pancreatic cancer compared with CA 19-9 and Dupan-2.

Cancer 60